Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma

Next Previous
Search
Trial Profile

A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 30 Oct 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs FT-516 (Primary) ; Cyclophosphamide; Dexamethasone; Elotuzumab; Fludarabine; Obinutuzumab; Pomalidomide; Rituximab
  • Indications Acute myeloid leukaemia; B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Haematological malignancies; Multiple myeloma; Non-Hodgkin's lymphoma
  • Focus Adverse reactions; First in man
  • Sponsors Fate Therapeutics

    • Most Recent Events

    • 25 Oct 2023 Status changed from active, no longer recruiting to discontinued. The study was terminated by the Sponsor.
    • 30 Apr 2023 Status changed from recruiting to active, no longer recruiting.
    • 03 Nov 2022 According to a Fate Therapeutics media release, the trial is currently enrolling patients in multiple disease-specific, multi-dose expansion cohorts at 900 million cells per dose.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top